Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study
Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study
复制标题
DOI：
10.1136/annrheumdis-2012-201612
复制
发表时间：
2013-06-01
影响因子：
27.4
通讯作者：
Burmester, Gerd-R
中科院分区：
文献类型：
--
作者：
Detert, Jacqueline;Bastian, Hans;Burmester, Gerd-R
目的观察阿达木单抗（ADA）联合甲氨蝶呤（MTX）诱导治疗与安慰剂（PBO）联合MTX治疗未接受过DMARD治疗的早期活动性类风湿关节炎（RA）患者的远期疗效。
Objective To investigate the long-term effects of induction therapy with adalimumab (ADA) plus methotrexate (MTX) in comparison with placebo (PBO) plus MTX in DMARD-naive patients with active early rheumatoid arthritis (RA).Methods Patients with active early RA (disease duration of